Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

休市中 10-24 16:00:00 EDT

70.86

-0.64

-0.90%

盘后71.20

+0.34+0.48%

19:54 EDT

最高72.44	最低70.22	成交量199.04万
今开72.39	昨收71.50	日振幅3.10%
总市值112.94亿	流通市值111.94亿	总股本1.59亿
成交额1.41亿	换手率1.26%	流通股本1.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":70.86,"timestamp":1761336000000,"preClose":71.5,"halted":0,"volume":1990370,"hourTrading":{"tag":"盘后","latestPrice":71.2,"preClose":70.86,"latestTime":"19:54 EDT","volume":13265,"amount":939997.54,"timestamp":1761350078953},"delay":0,"floatShares":157973603,"shares":159391229,"eps":-1.725196,"marketStatus":"休市中","change":-0.64,"latestTime":"10-24 16:00:00 EDT","open":72.39,"high":72.44,"low":70.22,"amount":141197166.2592,"amplitude":0.031049,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.725196,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1761552000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":71.5,"preHourTrading":{"tag":"盘前","latestPrice":71.91,"preClose":71.5,"latestTime":"09:28 EDT","volume":1043,"amount":74499.564622,"timestamp":1761312480004},"postHourTrading":{"tag":"盘后","latestPrice":71.2,"preClose":70.86,"latestTime":"19:54 EDT","volume":13265,"amount":939997.54,"timestamp":1761350078953},"volumeRatio":1.191762,"impliedVol":0.4336,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"2575743717","title":"Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2575743717","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575743717?lang=zh_cn&edition=full","pubTime":"2025-10-16 19:57","pubTimestamp":1760615844,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $75.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"大摩将Ionis Pharmaceuticals目标价从86美元上调至90美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONS"],"gpt_icon":0},{"id":"2574696851","title":"Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2574696851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574696851?lang=zh_cn&edition=full","pubTime":"2025-10-09 22:55","pubTimestamp":1760021747,"startTime":"0","endTime":"0","summary":"US biopharmaceutical companies are heading into a seasonally mixed Q3 with limited earnings surprises expected, while the investor focus shifts to upcoming clinical and corporate catalysts, BofA said Thursday in a research note previewing Q3 results.The firm said Ionis Pharmaceuticals  and Jazz Pharmaceuticals  were its top picks heading into year-end, citing strong clinical pipelines and event-driven upside.BofA adjusted several price objectives, raising Jazz to $230 from $225, Liquidia  to $37 from $35, Tarsus  to $85 from $80, and Teva  to $24 from $22, while trimming Amphastar  to $31 from $32.The analysts said they do not expect major Q3 beats or misses but highlighted upcoming events such as Jazz's phase 3 zanidatamab data in gastric cancer, Ionis' trial updates, and Teva's potential TAPI divestiture announcement.BofA maintained buy ratings on Ionis, Jazz, Liquidia, Tarsus, and Teva.Price: 70.11, Change: +0.15, Percent Change: +0.21","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"美国银行表示，随着美国生物制药进入稳定的第三季度，Ionis和Jazz被列为首选","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4596","BK4533","BK4584","TARS","LU0320765992.SGD","AMPH","BK4585","BK4532","IE00BN0W2W23.USD","IONS","TEVA","BK4588","LU0823416689.USD","BK4007","IE00BN0W2V16.EUR","LU1983299246.USD","BK4139","BK4566","BK4559","JAZZ","BK4557","LU0109394709.USD","LQDA","IE00BN0W2T93.GBP","LU0889565916.HKD"],"gpt_icon":0},{"id":"2574792849","title":"Ionis Pharmaceuticals Shares Rise After JPMorgan Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2574792849","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574792849?lang=zh_cn&edition=full","pubTime":"2025-10-09 02:41","pubTimestamp":1759948862,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals  shares rose 2.6% in recent Wednesday trading after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $80 per share from $49.Trading volume stood at nearly 1.7 million shares compared with a daily average of over 2.4 million.Price: 70.80, Change: +1.86, Percent Change: +2.69","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"摩根大通升级后Ionis Pharmaceuticals股价上涨","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONS"],"gpt_icon":0},{"id":"2570483908","title":"Ionis Pharmaceuticals Shares Rise After Goldman Sachs Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2570483908","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570483908?lang=zh_cn&edition=full","pubTime":"2025-09-27 02:45","pubTimestamp":1758912328,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals  shares were up about 1.7% in recent Friday trading after Goldman Sachs upgraded the stock to neutral from sell and raised its price target to $65 from $45.Trading volume stood at more than 792,000 shares, against a daily average of roughly 2.5 million.Price: 64.02, Change: +1.05, Percent Change: +1.66","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"高盛上调评级后Ionis Pharmaceuticals股价上涨","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONS"],"gpt_icon":0},{"id":"2569787421","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2569787421","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569787421?lang=zh_cn&edition=full","pubTime":"2025-09-22 21:16","pubTimestamp":1758546973,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed pre-bell Monday, with the Health Care Select Sector SPDR Fund  0.7% lower and the iShares Biotechnology ETF  up 0.2%.Pfizer  said it has entered into a definitive agreement to acquire Metsera  for $47.50 per share in cash, valuing the company at about $4.9 billion. Metsera shares were up more than 61% premarket.Premier  stock was up more than 8% after the company said it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital in a transaction valued at $2.6 billion.Ionis Pharmaceuticals  shares were up more than 2% after the company said the latest results from a study of zilganersen marked the first time that an investigational medicine showed a positive disease-modifying impact in Alexander disease.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"行业更新：医疗保健股周一盘前涨跌互现","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0321505439.SGD","IE000M9KFDE8.USD","LU1057294990.SGD","BK4139","BK4534","IE00BLSP4452.SGD","IONS","BK4568","LABU","LU0225771236.USD","MTSR","PINC","SG9999001176.SGD","BK4196","IE00BBT3K403.USD","LU1066053197.SGD","SG9999011175.SGD","XLV","IE00BLSP4239.USD","LU0234572021.USD","LU1883839398.USD","LU0225284248.USD","SG9999013999.USD","LU0170899867.USD","LU0122379950.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IE0002270589.USD","SG9999002232.USD","LU1894683348.USD","BK7095","LU0868494617.USD","LU0321505868.SGD","BK4581","BK4592","LU0306807586.USD","LU1023059063.AUD","BK4007","BK4550","LU1066051498.USD","PFE.AU","BK4599","IBB","LU0985481810.HKD","XBI","BK4585","BK4533","SG9999002224.SGD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2568257220","title":"Ionis Pharmaceuticals, Sobi's Familial Chylomicronemia Treatment Approved by EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2568257220","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568257220?lang=zh_cn&edition=full","pubTime":"2025-09-19 19:27","pubTimestamp":1758281249,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) and Sobi said Friday that Tryngolza has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familia","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Ionis Pharmaceuticals，Sobi家族性乳糜微粒血症治疗获欧盟批准","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","BK4139","IONS"],"gpt_icon":0},{"id":"1123195233","title":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1123195233","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123195233?lang=zh_cn&edition=full","pubTime":"2025-09-18 19:41","pubTimestamp":1758195688,"startTime":"0","endTime":"0","summary":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BIIB","BK4588","LU0320765992.SGD","BK4532","LU0109394709.USD","IE00B19Z9P08.USD","BK4585","BK4139","LU0889565916.HKD","BK4533","LU0234570918.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2566761970","title":"Update: Arrowhead Pharmaceuticals Sues Ionis Pharmaceuticals Over Plozasiran Patent Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2566761970","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566761970?lang=zh_cn&edition=full","pubTime":"2025-09-12 23:08","pubTimestamp":1757689708,"startTime":"0","endTime":"0","summary":"(Updates with Ionis' response in the fourth paragraph and the latest stock movement in the fifth paragraph.)Arrowhead Pharmaceuticals (ARWR) said Thursday it filed a complaint for declaratory judgment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"更新：Arrowhead Pharmaceuticals就Plozasiran专利纠纷起诉Ionis Pharmaceuticals","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IONS","BK4585","ARWR","BK4588"],"gpt_icon":0},{"id":"2564374201","title":"RBC Capital Adjusts Price Target on Ionis Pharmaceuticals to $80 From $70, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564374201","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564374201?lang=zh_cn&edition=full","pubTime":"2025-09-04 20:29","pubTimestamp":1756988992,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $68.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"RBC Capital将Ionis Pharmaceuticals目标价从70美元调整至80美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONS"],"gpt_icon":0},{"id":"2564315334","title":"Ionis Pharmaceuticals Shares Rise After BMO Capital Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2564315334","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564315334?lang=zh_cn&edition=full","pubTime":"2025-09-04 02:38","pubTimestamp":1756924702,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals  shares rose nearly 5% in recent Wednesday trading after BMO Capital upgraded the stock to outperform from market perform and increased its price target to $70 per share from $40.Trading volume stood at over 6.9 million compared with a daily average of about 2.2 million.Price: 60.31, Change: +2.82, Percent Change: +4.91","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"BMO资本升级后Ionis Pharmaceuticals股价上涨","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONS","BMO"],"gpt_icon":0},{"id":"1135242848","title":"BMO将Ionis Pharmaceuticals评级从市场表现上调至跑赢大盘，目标价从40美元上调至70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135242848","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135242848?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:01","pubTimestamp":1756897303,"startTime":"0","endTime":"0","summary":"BMO将Ionis Pharmaceuticals的评级从市场表现上调至跑赢大盘，同时将目标价从40美元大幅上调至70美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1197561614","title":"Ionis Pharmaceuticals高管表示急性胰腺炎患者平均住院17天，支付方成本高昂","url":"https://stock-news.laohu8.com/highlight/detail?id=1197561614","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197561614?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:16","pubTimestamp":1756818976,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示，急性胰腺炎患者平均住院时间长达17天，这对支付方来说成本非常高昂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1180606351","title":"Ionis Pharmaceuticals高管：严重高甘油三酯血症适应症获批时将公布定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180606351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180606351?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:07","pubTimestamp":1756818424,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals公司高管表示，该公司将在其严重高甘油三酯血症治疗适应症获得监管批准时公布相关药物的定价信息。这一表态显示该公司正在为其治疗严重高甘油三酯血症的药物制定市场准入策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2564807043","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2564807043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564807043?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:59","pubTimestamp":1756817946,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to lower premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) down 0.5%.Ionis Pharmaceuticals (IONS) shar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"行业更新：医疗保健","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IBB","BK4581","BK4585","XLV","IONS","BK4139"],"gpt_icon":0},{"id":"1120167759","title":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1120167759","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120167759?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:56","pubTimestamp":1756817811,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2564103802","title":"Leerink Partners Adjusts Price Target on Ionis Pharmaceuticals to $62 From $56, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564103802","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564103802?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:22","pubTimestamp":1756815724,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $60.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"Leerink Partners将Ionis Pharmaceuticals目标价从56美元调整至62美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONS"],"gpt_icon":0},{"id":"1133437325","title":"Ionis Pharmaceuticals：Olezarsen治疗严重高甘油三酯血症患者的关键3期Core和Core2研究获得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133437325","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133437325?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:24","pubTimestamp":1756812253,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布，其药物Olezarsen在治疗严重高甘油三酯血症患者的关键3期Core和Core2研究中取得积极的顶线结果。这一研究成果为该公司在代谢性疾病治疗领域的发展提供了重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1123660220","title":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123660220","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123660220?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:12","pubTimestamp":1756811553,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1197389364","title":"Ionis Pharmaceuticals宣布Olezarsen三期临床研究取得积极结果 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1197389364","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197389364?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:08","pubTimestamp":1756811300,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布其药物Olezarsen的三期临床研究取得积极结果，该消息通过SEC文件披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2561472079","title":"Sector Update: Health Care Stocks Rise Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2561472079","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561472079?lang=zh_cn&edition=full","pubTime":"2025-08-22 21:15","pubTimestamp":1755868531,"startTime":"0","endTime":"0","summary":"Health care stocks were rising pre-bell Friday, with The Health Care Select Sector SPDR Fund  0.4% higher and the iShares Biotechnology ETF  up 0.7%.Novo Nordisk  will reduce the current year bonuses for employees eligible for short-term incentives in Denmark due to slower growth and a lowered forecast, Bloomberg News reported, citing a company spokesperson. The company's shares were up more than 2% premarket.Keros Therapeutics'  largest stockholder, ADAR1 Capital Management, said it would like to \"work collaboratively\" with the board on strategy, capital allocation and potential board changes to unlock value for all shareholders. Keros Therapeutics stock was more than 1% higher pre-bell.Ionis Pharmaceuticals  shares were 1% higher after the company said the US Food and Drug Administration approved Dawnzera as the first and only RNA-targeted prophylactic treatment for preventing attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"行业更新：医疗保健股周五盘前上涨","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","BK4532","BK4585","BK4581","IE00BKVL7J92.USD","IONS","XLV","BK4139","KROS","LU0154236417.USD","LU1093756168.USD","BK4588","BK4007","IE00BZ1G4Q59.USD","BK4599","NVO.AU","IBB","BK7104"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.ionispharma.com","stockEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":0.1082},{"period":"3month","weight":0.6774},{"period":"6month","weight":1.3859},{"period":"1year","weight":0.8277},{"period":"ytd","weight":1.0269}],"compareEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":0.0244},{"period":"3month","weight":0.063},{"period":"6month","weight":0.2299},{"period":"1year","weight":0.1692},{"period":"ytd","weight":0.1556}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位，利用新药研发平台，公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台，公司可以用反义药物拓展自身及其合作伙伴的药物种类，满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物，使其成为关键的临床值转折点。公司发明并进行新药早期研究，然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值，如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO，正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.026725},{"month":2,"riseRate":0.5,"avgChangeRate":-0.015083},{"month":3,"riseRate":0.3,"avgChangeRate":-0.028033},{"month":4,"riseRate":0.4,"avgChangeRate":0.018094},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049558},{"month":6,"riseRate":0.8,"avgChangeRate":0.059464},{"month":7,"riseRate":0.8,"avgChangeRate":0.041363},{"month":8,"riseRate":0.5,"avgChangeRate":0.012224},{"month":9,"riseRate":0.5,"avgChangeRate":0.051342},{"month":10,"riseRate":0.2,"avgChangeRate":-0.031737},{"month":11,"riseRate":0.555556,"avgChangeRate":0.09545},{"month":12,"riseRate":0.444444,"avgChangeRate":0.0073}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.4","shortVersion":"4.35.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况